Sandbox:glomerular disease: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
! rowspan="2" |Glomerular Disease | ! rowspan="2" |Glomerular Disease | ||
! colspan="3" |Physical Examination | ! colspan="3" |Physical Examination | ||
! colspan=" | ! colspan="8" |Laboratory Studies | ||
! colspan="2" |Management | ! colspan="2" |Management | ||
! rowspan="2" |Prognosis | ! rowspan="2" |Prognosis | ||
| Line 14: | Line 14: | ||
!Serum Lipids | !Serum Lipids | ||
!C3/C4 | !C3/C4 | ||
! | !ANCA | ||
!Anti-GBM | |||
!Other Serologies | !Other Serologies | ||
!Initial Treatment | !Initial Treatment | ||
| Line 20: | Line 21: | ||
|- | |- | ||
|Diabetic Nephropathy | |Diabetic Nephropathy | ||
| | |||
| | | | ||
| | | | ||
| Line 40: | Line 42: | ||
| | | | ||
| +++ | | +++ | ||
| | |||
| | | | ||
| | | | ||
| Line 50: | Line 53: | ||
|- | |- | ||
|Primary FSGS | |Primary FSGS | ||
| | |||
| | | | ||
| | | | ||
| Line 65: | Line 69: | ||
|- | |- | ||
|Paraprotein Related Renal Disease | |Paraprotein Related Renal Disease | ||
| | |||
| | | | ||
| | | | ||
| Line 91: | Line 96: | ||
| | | | ||
| | | | ||
|PDN*;INN* | |||
|PDN*;AZA* | |||
| | | | ||
|- | |||
|Alport syndrome | |||
| | | | ||
| | | | ||
| | | | ||
| Line 109: | Line 116: | ||
| | | | ||
|- | |- | ||
|Goodpasture | |Goodpasture syndrome | ||
| | | | ||
| | | | ||
| Line 120: | Line 126: | ||
| | | | ||
| | | | ||
|✔ | |||
| | | | ||
|PDN*; INN*; PPH* | |||
| | | | ||
| | | | ||
|- | |- | ||
|Eosinophilic granulomatosis with polyangiitis | |||
| | | | ||
| | | | ||
| Line 132: | Line 141: | ||
| | | | ||
| | | | ||
|✔ | |||
| | | | ||
| | |Eosinophilia; IgE | ||
| | |PDN* | ||
| | |Non severe: PDN*; MTX*, AZA*, HU* | ||
Severe: PDN*; INN*; AZA* or MTX* | |||
| | | | ||
|- | |- | ||
|Microscopic polyangiitis | |||
| | | | ||
| | | | ||
| Line 147: | Line 159: | ||
| | | | ||
| | | | ||
|✔ | |||
| | | | ||
| | | | ||
| Line 152: | Line 165: | ||
| | | | ||
| | | | ||
|- | |||
| | | | ||
| | | | ||
| | | | ||
| Line 169: | Line 182: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| Line 184: | Line 198: | ||
| | | | ||
|} | |} | ||
<nowiki>*</nowiki> AZA=Azathioprine; HU=Hydroxyurea; INN=Cyclophosphamide; MTX=Methotrexate; PDN=Prednisone; PPH=Plasmapheresis | |||
__NOTOC__ | __NOTOC__ | ||
Latest revision as of 13:06, 16 November 2016
| Glomerular Disease | Physical Examination | Laboratory Studies | Management | Prognosis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood Pressure | Edema | Other Physical Manifestations | Proteinuria | Lipiduria | Albumin | Serum Lipids | C3/C4 | ANCA | Anti-GBM | Other Serologies | Initial Treatment | Maintenance Treatment | ||
| Diabetic Nephropathy | ||||||||||||||
| Minimal Change Disease | +++ | |||||||||||||
| Primary FSGS | ||||||||||||||
| Paraprotein Related Renal Disease | ||||||||||||||
| Granulomatosis with polyangitis | ✔ | PDN*;INN* | PDN*;AZA* | |||||||||||
| Alport syndrome | ||||||||||||||
| Goodpasture syndrome | ✔ | PDN*; INN*; PPH* | ||||||||||||
| Eosinophilic granulomatosis with polyangiitis | ✔ | Eosinophilia; IgE | PDN* | Non severe: PDN*; MTX*, AZA*, HU*
Severe: PDN*; INN*; AZA* or MTX* |
||||||||||
| Microscopic polyangiitis | ✔ | |||||||||||||
* AZA=Azathioprine; HU=Hydroxyurea; INN=Cyclophosphamide; MTX=Methotrexate; PDN=Prednisone; PPH=Plasmapheresis